SCHEMBL873082

SCHEMBL873082

C#CC1(OC(C)=O)CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11617059 1.00 MEN1 (0.38) MEN1POLBKMT2A
SCHEMBL2104316 0.83 MEN1 (0.36) MEN1POLBKMT2A
SCHEMBL2105441 0.83 MEN1 (0.36) MEN1POLBKMT2A
SCHEMBL30482273 0.82
SCHEMBL24574204 0.81 ALDH1A1 (0.34) MEN1POLBKMT2A
SCHEMBL11592104 0.81 MEN1 (0.35) MEN1POLBKMT2A
SCHEMBL2105585 0.80 MEN1 (0.40) MEN1POLBKMT2A
SCHEMBL2861221 0.79 ALDH1A1 (0.38) MEN1POLBKMT2A
SCHEMBL30999761 0.79 MEN1 (0.39) MEN1POLBKMT2A
SCHEMBL23183058 0.79 ALDH1A1 (0.35) MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4655373-A1 BIODEGRADABLE PERFUME COMPOSITION Givaudan SA (CH) 2025-12-03 EP claimed
WO-2024156688-A1 BIODEGRADABLE PERFUME COMPOSITION GIVAUDAN SA (CH) 2024-08-02 WO claimed
EP-4407019-A1 BIODEGRADABLE PERFUME COMPOSITION Givaudan SA (CH) 2024-07-31 EP claimed
US-20230365523-A1 PROCESS FOR PREPARING 3-(CYCLOHEX-1-EN-1-YL)PROPANAL DERIVATIVES FIRMENICH SA (CH) 2023-11-16 US claimed
EP-4153552-A2 PROCESS AND INTERMEDIATES FOR PREPARING 3-(CYCLOHEX-1-EN-1-YL) PROPANAL DERIVATIVES Firmenich SA (CH) 2023-03-29 EP claimed
WO-2022049036-A2 PROCESS FOR PREPARING 3-(CYCLOHEX-1-EN-1-YL)PROPANAL DERIVATIVES FIRMENICH SA (CH) 2022-03-10 WO claimed
WO-2018145219-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING SERANI MOSTAZAL JORGE (CL) 2018-08-16 WO claimed
EP-4655373-A1 BIODEGRADABLE PERFUME COMPOSITION Givaudan SA (CH) 2025-12-03 EP disclosed
WO-2024156688-A1 BIODEGRADABLE PERFUME COMPOSITION GIVAUDAN SA (CH) 2024-08-02 WO disclosed
EP-4407019-A1 BIODEGRADABLE PERFUME COMPOSITION Givaudan SA (CH) 2024-07-31 EP disclosed
US-11920104-B2 Ethers and esters of 1-substituted cycloalkanols for use as aroma chemicals BASF SE (DE) 2024-03-05 US disclosed
US-20230365523-A1 PROCESS FOR PREPARING 3-(CYCLOHEX-1-EN-1-YL)PROPANAL DERIVATIVES FIRMENICH SA (CH) 2023-11-16 US disclosed
EP-4153552-A2 PROCESS AND INTERMEDIATES FOR PREPARING 3-(CYCLOHEX-1-EN-1-YL) PROPANAL DERIVATIVES Firmenich SA (CH) 2023-03-29 EP disclosed
US-4091107-A RENAL VASODILATORS, ANTICLOTTING AGENTS, GROWTH HORMONE RELEASE, REGULATORS OF IMMUNE RESPONSE MERCK & CO., INC. (US) 1978-05-23 US disclosed
US-4085125-A 9-Thia-, 9-oxothia-, and 9-dioxothia-11,12-seco-prostaglandins and processes MERCK & CO., INC. (US) 1978-04-18 US disclosed
US-4066692-A 11,12-SECOPROSTAGLANDINS MERCK & CO., INC. (US) 1978-01-03 US disclosed
US-4066675-A PSORIASIS, THROMBOSIS MERCK & CO., INC. (US) 1978-01-03 US disclosed
US-4033996-A RENAL VASODILATORS, ANTITHROMBOSIS, GROWTH HORMONE RELEASING MERCK & CO., INC. (US) 1977-07-05 US disclosed
US-4018802-A SKIN DISEASES, GROWTH HORMONE STIMULANTS, THROMBUS PREVENTION, IMMUNOLOGY MERCK & CO., INC. (US) 1977-04-19 US disclosed
US-3989749-A RENAL VASODILATORS, ANTITHROMBUS MERCK & CO., INC. (US) 1976-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365523-A1 PROCESS FOR PREPARING 3-(CYCLOHEX-1-EN-1-YL)PROPANAL DERIVATIVES CYP1A1, CYP51A1, HPD MEN1 3898/4885POLB 179/4885KMT2A 4682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.